Coya delivers ‘strong’ POC data for AD, ALS for coming catalysts, milestones

Coya Therapeutics released the following letter to stockholders from its Chief Executive Officer and Chairman, Dr. Howard Berman: ” As promised, we have now generated what we consider strong clinical proof of concept, POC, data in Alzheimer’s Disease AD and Amyotrophic Lateral Sclerosis ALS . We believe this data is driving excitement for our regulatory T cell or Treg-modulating approach and represents the first in an ongoing series of important catalysts we believe we can deliver throughout this year and next. Momentum is building. Moreover, we will continue to look for business development opportunities that I believe have the potential to dramatically expand our options for ongoing stockholder value creation. We intend to pursue catalysts and milestones in 2023 and 2024 that we expect will drive our success.”